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ABSTRACT 86 
 87 
Background: β-lactam antibiotics are associated with a variety of immune-mediated 88 
or hypersensitivity reactions, including immediate (Type I) reactions mediated by 89 
antigen-specific IgE.   90 
 91 
Objective: To identify genetic predisposing factors for immediate reactions to β-92 
lactam antibiotics. 93 
 94 
Methods: Patients with a clinical history of immediate hypersensitivity reactions to 95 
either penicillins or cephalosporins, which were immunologically confirmed, were 96 
recruited from allergy clinics. A genome-wide association study (GWAS) was 97 
conducted on 662 patients (the discovery cohort) with a diagnosis of immediate 98 
hypersensitivity and the main finding was replicated in a cohort of 98 Spanish cases, 99 
recruited using the same diagnostic criteria as the discovery cohort.  100 
 101 
Results: GWAS identified rs71542416 within the Class II HLA region as the top hit 102 
(P = 2x10-14); this was in linkage disequilibrium with HLA-DRB1*10:01 (OR = 2.93 P = 103 
5.4x10-7) and HLA-DQA1*01:05 (OR=2.93, P=5.4x10-7).  Haplotype analysis identified 104 
that HLA-DRB1*10:01 was a risk factor even without the HLA-DQA1*01:05 allele.  105 
The association with HLA-DRB1*10:01 was replicated in another cohort, with the 106 
meta-analysis of the discovery and replication cohorts showing that HLA-DRB1*10:01 107 
increased the risk of immediate hypersensitivity at a genome-wide level (OR = 2.96 108 
P=4.1x10-9).  No association with HLA-DRB1*10:01 was identified in 268 patients 109 
with delayed hypersensitivity reactions to β-lactams.   110 
 111 
Conclusion: HLA-DRB1*10:01 predisposed to immediate hypersensitivity reactions 112 
to penicillins. Further work to identify other predisposing HLA and non-HLA loci is 113 
required.   114 
 115 
 116 
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Clinical implications: This novel insight into the mechanisms of immediate 117 
reactions associated with penicillins may be of use in risk stratifying patients where 118 
penicillin cannot be excluded as an etiological agent.   119 
 120 
CAPSULE SUMMARY 121 
Predisposition to immediate hypersensitivity reactions to penicillins is mediated by 122 
HLA-DRB1*10:01, and may help in risk stratifying patients where penicillin cannot be 123 
excluded as an etiological agent. 124 
 125 
KEY WORDS: Type I hypersensitivity, β-lactams, penicillins, cephalosporins, 126 
allergy, anaphylaxis, pharmacogenomics.  127 
 128 
ABBREVIATIONS 129 
• ADR  Adverse Drug Reaction 
• AGEP  Acute generalised exanthematous pustulosis 
• BL  β-Lactam 
• DNA  Deoxyribonucleic acid 
• DRESS  Drug reaction with eosinophilia and systemic symptoms 
• GWAS  Genome-wide association study 
• HLA  Human Leukocyte Antigen 
• HPEPT1  human peptide transporter 1  
• ITCH  International Consortium on Drug Hypersensitivity 
• OR  Odds Ratio 
• SJS/TEN  Stevens-Johnson syndrome/toxic epidermal necrolysis 
• SNP  Single Nucleotide Polymorphism 
• WTCCC  Wellcome Trust Case Control Consortium  
   130 
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INTRODUCTION 131 
 132 
β-lactam (BL) antibiotics cause a wide spectrum of hypersensitivity reactions 133 
(sometimes termed allergy).  The self-reported incidence of BL allergy ranges from 134 
1% to >10%1, but in clinic populations most patients (~95%) are not found to be 135 
truly allergic with validated skin testing and oral challenge. Indeed, a high proportion 136 
are intolerant2 as adverse effects such as diarrhea after the use BLs are often 137 
mistakenly reported as allergy by patients. 138 
 139 
True BLs hypersensitivity reactions are classified according to the time of onset of 140 
the reaction following drug intake3. Immediate hypersensitivity reactions develop in 141 
minutes or hours after drug intake and are due to cross-linking of specific IgE 142 
molecules on the mast cell surface with release of vasoactive mediators such as 143 
histamine leading to vasodilation,  increased vascular permeability and smooth 144 
muscle contraction4. Clinically this is manifested as urticaria, angioedema, 145 
bronchospasm and hypotension. Anaphylaxis is the most severe and feared form of 146 
immediate hypersensitivity.  By contrast, delayed hypersensitivity reactions occurring 147 
>6h after dosing are typically T-cell mediated and have variable manifestations 148 
including maculopapular exanthem, DRESS (drug reaction with eosinophilia and 149 
systemic symptoms) and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis3.  150 
 151 
Medicines are amongst the main cause of fatal anaphylaxis with a mortality rate 152 
higher than with other agents5. Penicillins and cephalosporins are still the two most 153 
common drug classes associated with anaphylaxis6, with penicillins having a higher 154 
incidence (1-5 per 100,000)7 compared to cephalosporins1. Cross-reactivity between 155 
penicillins, cephalosporin and other BLs not sharing an R1 or R2 side-chain is now 156 
thought to be <2%8, 9.  157 
 158 
Potential clinical risk factors for immediate hypersensitivity reactions are family 159 
history, atopy,  concomitant virus infections and the route of administration10.  160 
Genetic predisposing factors have also been identified10: the most comprehensive 161 
was an analysis of 107,398 single nucleotide polymorphisms which identified that the 162 
HLA-DRA locus may protect against penicillin-induced immediate hypersensitivity 163 
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reactions11.  In order to further investigate the role of genetic factors in BL-induced 164 
immediate hypersensitivity reactions, we have undertaken a GWAS (genome-wide 165 
association study) of the largest deeply phenotyped patient cohort assembled so far.   166 
 167 
METHODS 168 
 169 
Cases 170 
All subjects were recruited between 2009 and 2013 as part of International 171 
Consortium on Drug Hypersensitivity (ITCH), involving 5 recruitment centers 172 
worldwide (Australia, France, Italy, Spain, UK).  The study was approved by ethics 173 
committees in all countries, and all patients gave written informed consent. 174 
 175 
We recruited 662 patients (the discovery cohort) with a diagnosis of immediate 176 
hypersensitivity to BL antibiotics (table 1).  The diagnosis of immediate 177 
hypersensitivity was made in specialist allergy clinics, as per published criteria12.  All 178 
patients required immunological assessment (total and specific IgE, skin testing 179 
including skin prick and intradermal and/or oral provocation) as part of the inclusion 180 
criteria.  Independent adjudication of all cases was undertaken by NS and PF.  For 181 
replication of any signals, we separately recruited another 98 patients with 182 
immediate hypersensitivity from a clinic in Spain, diagnosed according to the same 183 
criteria. 184 
 185 
To determine specificity of any signals identified in patients with immediate 186 
hypersensitivity, we also evaluated 268 patients with delayed hypersensitivity 187 
reactions across multiple beta-lactams.  The diagnosis again was in accordance with 188 
published guidance12, and all cases were adjudicated by NS and PF.  We also included 189 
an additional 17 BL-induced delayed hypersensitivity reaction cases analyzed in Shen 190 
et al13. 191 
 192 
Controls  193 
We used general population samples as study controls. This comprised 9217 194 
European ancestry controls from multiple available sources enriching the group with 195 
Spanish, Italian and north European origin samples since cases were manly recruited 196 
from those countries. We used the Wellcome Trust Case Control Consortium 197 
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(WTCCC) (http://www.wtccc.org.uk), the population reference sample (POPRES)14, 198 
PGX400011913, LAM3000413 and Spanish Bladder cancer cohort (phs000346.v1)15 199 
from dbGAP, Hypergenes cohort (http://www.hypergenes.eu/), the National Spanish 200 
DNA Bank (http://www.bancoadn.org/), and TSI (Hapmap data). In addition, we also 201 
recruited a group of 137 penicillin tolerant controls from Italy.  202 
 203 
Genotyping 204 
Genome-wide genotyping of DNA extracted from whole blood was performed at 205 
the Broad Institute, Boston, for 662 cases with BL-induced immediate 206 
hypersensitivity and 268 cases with delayed hypersensitivity reaction, and from 137 207 
penicillin tolerant controls from Italy. In 474 (354 BL-induced immediate and 120 BL-208 
induced delayed) cases, the Illumina Infinium HumanCoreExome Bead Chip was used 209 
while for 439 (308 BL-induced immediate and 131 BL-induced delayed) cases, the 210 
Illumina HumanOmniExpress BeadChip was used. In this last batch, we also 211 
genotyped 137 Italian penicillin tolerant controls. In addition, the BL-induced delayed 212 
case group also included 17 β-lactam delayed hypersensitivity cases previously 213 
genotyped by the Illumina 1M Duo chip, extracted from a larger SJS/TEN study that 214 
included multiple drugs, as described by Shen et al.13.  Other control cohorts were 215 
publicly available (Table S1). For each of the genotyping cohort, standard quality 216 
control was conducted at both single marker and subject levels as previously 217 
described13. This was followed by SNP and HLA imputation and amino acid analysis 218 
(see supplement).  219 
 220 
Replication Cohort SNP and HLA genotyping 221 
The top associated imputed single nucleotide polymorphisms (SNPs) were validated 222 
by SNP genotyping using either TaqMan, SNP genotyping assays (ThermoFisher 223 
Scientific, Paisley, UK) or iPLEX MassArray genotyping platform (Agena Biosciences, 224 
Hamburg, Germany). High resolution genotyping of HLA-A, B, C, DRB1, DQA1 and 225 
DQB1 was performed by Histogenetics (Ossining, New York). Sequencing data files 226 
were analyzed using Histogenetics’ proprietary analysis software (Histomatcher and 227 
HistoMagic) for HLA genotype calling. Allele assignments are based on IMGT/HLA 228 
Database release version 2.21.0, dated April 2008 (http://www.ebi.ac.uk/imgt/hla/). 229 
 230 
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Statistical analysis 231 
The effect of population structure was assessed through principal component 232 
analysis (PCA) using the smartPCA program from the EIGENSTRAT package 233 
(version 3.0)16. Single marker and haplotype association analyses and heterogeneity 234 
test analyses were carried out by PLINK 1.0717. The statistical association of each 235 
marker, HLA alleles and SNPs, was determined in a logistic regression framework 236 
with scores for the first seven principal components as covariates under an additive 237 
model using PLINK. We used the same statistical test for sub-population analyses, 238 
using two, seven and ten most significant principal components as covariates in 239 
Italian, Spanish and North European populations, respectively. We set the genome-240 
wide traditional significance P-value threshold to 5.0x10-8 to correct for multiple 241 
testing and MHC-wide significance threshold to 2.0x10-4 to correct for total number 242 
of predicted alleles. When we obtained genome-wide significant signals, we tested 243 
for independent effects from the neighboring variants by including the most 244 
associated variants as a covariate and then testing the significance of others in the 245 
region.  All detailed analyses and Manhattan plots were performed with R (Version 246 
3.0.2). Regional plots were drawn by LocusZoom18. Meta-analysis was performed 247 
using a fixed-effect model in the metafor package (http://www.metafor-248 
project.org/doku.php/metafor). 249 
 250 
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RESULTS 252 
 253 
Patient cohorts 254 
The clinical characteristics of the patients are shown in table 1.  Clinical 255 
manifestations in the discovery cohort included angioedema (35%), bronchospasm 256 
(24%) and urticaria (34%), while hypotension was reported in only 4% of cases. The 257 
length of reaction in patients with immediate hypersensitivity was 2-11 days, while it 258 
ranged from 21-26 days for patients with delayed hypersensitivity reactions. Patients 259 
were included if they had positive diagnostic assessment, as highlighted in table 1.  260 
Penicillins accounted for 75% of cases, with the most common culprit drug being 261 
amoxicillin accounting for 58% of cases in the discovery cohort.   262 
 263 
Association with immediate reactions to beta-lactams 264 
We first conducted a genome wide association study on 662 patients of European 265 
descent with immediate hypersensitivity reactions and 9217 previously genotyped 266 
population controls matched for ethnicity. The total number of SNPs which were 267 
included in the analyses after quality control was 4,265,742.  The cases clustered 268 
within three major groups (Italian, Spanish and Northern European, Figure S1) in 269 
keeping with the self-reported ethnicity.  270 
 271 
A genome-wide significant association was identified within the Class II HLA region, 272 
rs71542416 being the top hit (OR=5.17; 95% CI 3.40-5.17; P=2x10-14; Table 2, Figure 273 
1A and Figure S2). The frequency of rs71542416 in our control population was 274 
comparable with publicly available sources (Table 2). HLA allele imputation using 275 
HIBAG19 showed the HLA-DRB1*10:01 (OR=2.95; 95% CI 1.99-4.36; P=6.0x10-8) and 276 
HLA-DQA1*01:05 (OR=2.93 95%CI 1.92-4.45 P=5.4x10-7) alleles to be significantly 277 
associated with the immediate reactions, with consistent odds ratios (Table 2) and 278 
were tagged by rs71542416 (r2 0.76). Haplotype analysis identified that HLA-279 
DRB1*10:01 was a risk factor even without the HLA-DQA1*01:05 allele (Table S2). 280 
HLA-DRB1*10:01 was seen in 3% of cases and less than 1% of controls. The 281 
frequency of the HLA alleles within the Italian penicillin tolerant controls was 10 282 
times less than in the Italian general population (0.1% vs 1%).  283 
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The HLA allele effect size was similar across the three major clusters (heterogeneity 284 
test P = 0.11) (Table 3). The positive predictions in cases were fully validated by 285 
direct HLA typing.  An additional 67 cases with low quality predictions in both the 286 
loci were also typed.  Among them, we found only one positive carrier for HLA-287 
DRB1*10:01. All cases were also genotyped for rs71542416 – this showed a 288 
concordance of 99% between typed and imputed genotypes of rs71542416.  HLA-289 
DRB1*10:01 co-occurred with rs71542416 in 89% of the HLA-DRB1*10:01 positive 290 
patients, while 12% of all cases carried rs71542416 alone.  291 
 292 
Including rs71542416 or the HLA alleles as covariates revealed a residual protective 293 
effect of the HLA-DRA locus, tagged by rs114632839, an intronic gene variant, in 294 
accordance with the findings of Gueant et al11 (Table 2 and Figure S3A). Interestingly 295 
GTEx analysis revealed that this variant was a strong eQTL for HLA-DRB5 (P = 296 
5.3x10-23) and sQTL for the HLA-DRB1 (P = 1.1x10-16), HLA-DRB5 (P=1.1x10-16) and 297 
HLA-DRB6 (P = 1.1x10-16) loci with the minor alleles showing a lower intron excision 298 
ratio.  Both effects were detected in whole blood and shared across other tissues 299 
(Figure S3B). 300 
 301 
A replication cohort of 98 patients with anaphylaxis induced by either amoxicillin or 302 
amoxicillin-clavulanate (table 1) was recruited separately from Spain.  We identified 7 303 
individuals who were positive for HLA-DRB1*10:01, as confirmed by HLA typing. 304 
Comparison using the 11 Spanish HLA typed cohorts reported in allelefrequency.net 305 
provided a total of 3137 Spanish subjects (Figure S4) as ethnically matched 306 
population controls.  This analysis replicated the association with an odds ratio (OR) 307 
of 2.80 (95% CI 1.17-6.71; Fisher Exact Test P=0.016; Figure 1B).  308 
 309 
Meta-analysis of the discovery and replication cohorts showed that HLA-DRB1*10:01 310 
increased the risk of immediate hypersensitivity at a genome-wide level (OR=2.96; 311 
95% CI 1.99-4.37; P =4.1x10-9) (Figure 2).  The sensitivity and specificity of the allele 312 
is 0.06 and 0.98, respectively, while the positive and negative predictive values are 313 
17% and 94% respectively. 314 
 315 
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The most significantly associated amino acid with immediate hypersensitivity 316 
reactions was glutamate at position 10 (OR=2.72; 95% CI 1.81-4.08; P=1.4x10-6, 317 
Table S3). Amoxicillin, amoxicillin-clavulanic acid and phenoxymethylpenicillin 318 
showed the highest effect size (Table S4). Glutamate-10 co-occurred with other 319 
amino acids (arginine-30, valine-31, alanine-38, tyrosine-40, proline-231, glutamine-320 
166) which had the same frequency in cases and controls as glutamate-10  and HLA-321 
DRB1*10:01 (Table S3).  However, association with these amino acids disappeared 322 
after condition for either glutamate-10 or HLA-DRB1*10:01 (Table S3).  Interestingly, 323 
glutamate-10 co-occurred with the shared epitope RRA at positions 70, 71 and 74, 324 
previously associated with seropositive rheumatoid arthritis20 and specific for the 325 
HLA-DRB1*10:01 allele. The ERRA haplotype increased risk (OR=2.72, P=1.4x10-6) 326 
equivalent to that seen with glutamate-10 alone. None of the other risk/protective 327 
amino acid motifs for seropositive rheumatoid arthritis20 spanning positions 70 to 74 328 
in the DRB1 locus (such as “QRRAA” risk motif or “DERAA” and “DRRAA” 329 
protective motifs) were associated with our phenotype.  330 
 331 
HLA analysis in patients with delayed hypersensitivity reactions 332 
To determine whether the association with HLA-DRB1*10:01 was limited to patients 333 
with immediate hypersensitivity reactions, we analyzed 268 patients with delayed 334 
hypersensitivity to a variety of BLs (Table 1) using the same control set (Figure S1B).  335 
No association was identified for HLA-DRB1*10:01 (n=249; OR = 1.34; 95% CI 0.55-336 
3.26; P=0.5).   337 
 338 
Drug specific associations with immediate hypersensitivity 339 
HLA-DRB1*10:01 was associated with penicillins as a class (OR=3.07), but not with 340 
cephalosporins (Table 4). Among the penicillins, the strongest signals were for 341 
amoxicillin (OR=3.48), amoxicillin clavulanic acid (OR=2.85) and phenoxymethyl 342 
penicillin (OR=6.66) (Table 4). When we combined amoxicillin and amoxicillin 343 
clavulanic acid cases (assuming that amoxicillin rather than clavulanic acid was the 344 
culprit), the OR was 3.1 (95%CI 2.01-4.85; P=4.0x10-7).  Additional drug-specific HLA 345 
allele associations that we identified will need confirmation (Tables S5 and S6).    346 
 347 
Jo
urn
al 
Pr
-pr
oo
f
 12 | P a g e  
 
In the drug-specific analysis, a genome-wide signal (rs71437970) on chromosome 13 348 
upstream of SLC15A1 (Figure S5) was identified for the amoxicillin cases (OR= 2.94 P 349 
=3.8x10-9, Table S6). This association was shared across the European 350 
subpopulations and with amoxicillin-clavulanate cases (Tables S7 and S8). However, 351 
we failed to replicate the association, with an allele frequency which was lower than 352 
that observed in Spanish controls (0.007 vs 0.04).  353 
 354 
DISCUSSION 355 
We have identified an association between the SNP rs71542416 and immediate 356 
hypersensitivity reactions to penicillins.  The SNP does not affect gene expression in 357 
GTEx but is in linkage disequilibrium with HLA-DRB1*10:01 and HLA-DQA1*01:05.  358 
Haplotype analysis identified that HLA-DRB1*10:01 was a risk factor even without the 359 
HLA-DQA1*01:05 allele suggesting that HLA-DRB1*10:01 may be the predominant 360 
driver of the association. However, 12% of cases carried rs71542416 but were 361 
negative for HLA-DRB1*10:01 suggesting that the SNP may be a tag for other rare 362 
HLA alleles, which is consistent with the hypothesis of Heap at al21 who showed an 363 
association between HLA-DQA1-HLA-DRB1 variants and thiopurine-induced 364 
pancreatitis.   365 
 366 
The association with HLA-DRB1*10:01 and rs71542416 was most pronounced in the 367 
Spanish cohort (Table 3), but given that the odds ratios were of similar magnitude in 368 
all populations studied, there was overlap in the confidence intervals, and the 369 
prevalence of the SNP and HLA allele, our findings can be generalized across the 370 
European sub-ethnicities studied (Table 3).  However, further studies will be needed 371 
in both European and non-European populations to determine the global relevance 372 
of this association.  Additionally, the association was limited to immediate reactions 373 
and was not observed with the delayed hypersensitivity reactions highlighting the 374 
specific nature of the association.  Evaluation of drug-specificity showed associations 375 
with amoxicillin, amoxicillin-clavulanate and phenoxymethylpenicillin.  However, 376 
given the limited sample size with the other penicillins, we cannot exclude the 377 
possibility of an association with all penicillins (Table 4).  Similarly, we did not find an 378 
association with cephalosporins, but this may also be because of a lower sample size.   379 
 380 
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The clear strength of our study is that all patients were deeply phenotyped: there 381 
was a clear clinical history with a temporal relationship to drug intake, and the 382 
diagnosis was confirmed immunologically by skin testing and/or oral provocation.  383 
Such deep phenotyping is important because many patients claim to be penicillin 384 
allergic, but very few are: of those claiming to be allergic, less than 1 In 20 have an 385 
acute reaction to an oral challenge (the gold standard clinical test to confirm an IgE-386 
mediated reaction)22.   387 
 388 
Our data adds to the increasing evidence of HLA in predisposing to different clinical 389 
phenotypes of drug hypersensitivity reactions23.  The most well-known of these 390 
associations is HLA-B*57:01 and abacavir hypersensitivity24, which has been 391 
implemented into clinical practice and has resulted in a significant reduction in 392 
abacavir hypersensitivity25.  It is important to note that most of the HLA associations 393 
identified to date have been with delayed hypersensitivity reactions23.  However, 394 
more recent studies have identified HLA alleles as predisposing factors for 395 
immediate reactions.  For instance, HLA-DRB1*07:01 is a risk factor for the 396 
development of anti-asparaginase antibodies and immediate reactions26.  Our data 397 
showing that HLA-DRB1*10:01 predisposes to immediate hypersensitivity is also 398 
consistent with the pathogenesis of immediate reactions where the interaction 399 
between B cells and CD4+/Th2-positive cells, through HLA class II alleles, is central 400 
to the immunoglobulin switching that leads to the generation of specific IgE 401 
antibodies. Different HLA alleles have been associated with other types of immune-402 
mediated reactions caused by BLs.  For example, HLA-B*57:01 predisposes to 403 
flucloxacillin-induced cholestatic hepatitis27, while liver injury caused by amoxicillin-404 
clavulanate is associated with the class II HLA haplotype HLA-DRB1*1501-405 
DQB1*060228.  Mechanistic studies undertaken in our laboratory have shown that 406 
drug-specific, HLA-restricted T cells can be isolated from patients with a past history 407 
of liver injury due to flucloxacillin29 and amoxicillin-clavulanate30.  It will be valuable to 408 
conduct similar studies in patients with a history of penicillin-induced immediate 409 
reactions to understand the mechanistic basis of the association with HLA-410 
DRB1*10:01.   411 
 412 
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Another potentially interesting finding in this study was the association between 413 
SLC15A1 gene variants and amoxicillin-induced immediate reactions.  SLC15A1 414 
encodes the human peptide transporter 1 (HPEPT1) which is known to transport 415 
amoxicillin31.  Therefore, it is plausible that variation in the activity of HPEPT1 could 416 
result in altered amoxicillin pharmacokinetics and thereby increase risk of a type I 417 
reaction.  However, we were not able to replicate this finding, and further work 418 
(including functional studies) to understand whether this gene is important in 419 
predisposing to immediate reactions will be required.   420 
 421 
What are the clinical implications of this finding?  Given the rarity of penicillin-422 
induced anaphylaxis, the low population prevalence and sensitivity of HLA-423 
DRB1*10:01, and the very wide usage of penicillins, the prospective use of this allele 424 
in screening patients before penicillin prescription would not be practical or feasible 425 
in terms of both high numbers needed to test to prevent one case and patients 426 
unnecessarily excluded from therapy. However, this association of immediate 427 
penicillin hypersensitivity with HLA-DRB1*10:01 may provide much novel insights into 428 
the mechanisms of immediate reactions associated with penicillins, including the 429 
mechanisms of sensitization and natural loss or waning of penicillin which is known 430 
to occur over time.  Moreover, the higher negative predictive value of the allele 431 
(94%) may be of use in risk stratifying patients where penicillin cannot be excluded as 432 
an etiological agent in the setting of an immediate reaction.   433 
 434 
Our study has limitations.  First, the overall sample size is small compared to that 435 
used in complex diseases but is larger than that used in many pharmacogenomic 436 
studies.  Our efforts to identify deeply phenotyped patients in this study was a result 437 
of an extensive international collaboration highlighting the difficulties in achieving 438 
large sample sizes in pharmacogenomic studies.  Furthermore, we were unable to 439 
perform permutation testing to validate the replication P value for HLA-DRB1*10:01. 440 
Second, because we used population controls, we could not adjust for self-reported 441 
ethnicity, but this is unlikely to have had a major impact as we accounted for this 442 
through an analysis of population stratification (figure S1).  Third, matching cases and 443 
controls for age, gender and other co-morbidities was not possible because of the 444 
use of population controls, and because gender could not be determined due to the 445 
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absence of X chromosome SNP data.  Whether this impacts on the association with 446 
the genetic signals identified by us will require further study. 447 
 448 
In summary, we have for the first time reported an association of HLA-DRB1*10:01 449 
carriage in deeply immunologically phenotyped European ancestry individuals with 450 
penicillin-induced immediate type I hypersensitivity reactions.  However, we cannot 451 
exclude the possibility of other HLA alleles or HLA haplotypes also being important 452 
in conferring susceptibility in some patients, and therefore further work in both 453 
European and non-European patients is required to identify other HLA alleles, and 454 
also whether HLA-DRB1*10:01 is universally important.  It is also interesting to note 455 
that we also identified that rs114632839 which is a proxy for the HLA-DRA locus 456 
protected against the development of immediate hypersensitivity reactions to BLs, 457 
consistent with a previous study11.  rs114632839 is an eQTL and sQTL for several 458 
HLA loci suggesting that predisposition to immediate hypersensitivity to penicillins is 459 
likely to be complex and mediated by a combination of susceptibility and protective 460 
HLA and non-HLA alleles.  Clearly we have reported associations, and proof of 461 
causality will require a full understanding of the immunopathogenesis of initial 462 
sensitization to penicillin, and in particular, the mechanism of antigen presentation 463 
(including the relative importance of the BL ring vs the side chains) and interaction 464 
with CD4+ T cells that ultimately leads to IgE-switching and the generation of 465 
hapten-specific IgE antibodies. 466 
 467 
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 602 
 603 
 604 
 605 
Figure Legend 606 
 607 
Figure 1 Genomic data in patients with immediate hypersensitivity reactions. A: 608 
Manhattan plot displaying the association analysis undertaken in patients with 609 
immediate hypersensitivity reactions to β-lactams (n=662). SNPs in green have a 610 
significance level less than 5x10-6 and red have a significance level less than 5x10-8. B: 611 
Forest plot showing the effect size of the association between HLA-DRB1*10:01 and 612 
immediate reactions in the discovery and replication cohorts. For each analysis, the 613 
odd ratio of the association is reported with 95% CI. The dimension of the squares is 614 
proportional of the number of cases. 615 
 616 
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Table 1:  Causative drugs and clinical variables broken down across the discovery 620 
and replication cohorts 621 
Clinical characteristics Immediate 
hypersensitivity 
Discovery 
cohort (n = 662) 
Immediate 
hypersensitivity 
Replication 
cohort (n = 98) 
Delayed 
hypersensitivity 
cohort (n = 268) 
Female (%) 416 (62%) 56 (57%) 174 (64%) 
Age years: mean, SD* 
(%missing) 
42.0, 16 (27%) 51.4, 12.3 (0%) 44.5, 20 (73%) 
History of allergies (n with 
available information) 
31% (658) 9% (98) 30.6% (268) 
Number of ADRs*: mean, 
SD* (#available info) 
1.1, 0.3 (659) 1.2 (0.5) 1, 0.2 (251) 
Autoimmune disease 
diagnosis 
9% 6% 7% 
% positive skin test (of total 
number tested) 
85% (578) 78% (67) 93% (204) 
% positive prick test (of 
total number tested) 
45% (142) 37% (82) 82% (207) 
% positive oral provocation 
/re-challenge (of total 
number tested) 
76% (106) 65% (20) 94% (17) 
Clinical symptoms 
Immediate hypersensitivity 
manifestations¶ 
662 (100%) 98 (100%) - 
AGEP* - - 14 (5%) 
DRESS* - - 7 (3%) 
Mild reactions including 
maculopapular exanthem 
- - 212 (79%) 
SJS/TEN* - - 36 (13%) 
Drug Class 
Penicillin 501 (75%) 98 (100%) 246 (92%) 
Cephalosporin 162 (25%) - 20 (7.5%) 
Other β-lactams - - 2 (0.01%) 
Suspected causal drug 
Amoxicillin 165 (25%) 65 (66%) 77 (29%) 
Ampicillin 36 (5%) - 54 (20%) 
Bacampicillin 20 (3%) - 21 (8%) 
Cefaclor 23 (3%) - - 
Cefazolin 17 (3%) - 4 (1.5%) 
Cefotaxime 17 (3%) - - 
Ceftazidime 18 (3%) - 1 (0.4%) 
Ceftriaxone 52 (8%) - 4 (1.5%) 
Cefuroxime 14 (3%) - 2 (0.7%) 
Co-amoxiclav 218 (33%) 26 (26%) 70 (26%) 
Phenoxymethylpenicillin 24 (4%) 7 (7%) 5 (2%) 
Piperacillin 18 (3%) - 5 (2%) 
Other 41 (6%) - 25 (9%) 
*ADRs: adverse drug reactions; AGEP: acute generalised exanthematous pustulosis, DRESS: drug reaction with 622 
eosinophilia and systemic symptoms; SD: standard deviation;  SJS/TEN: Stevens-Johnson Syndrome/Toxic 623 
Epidermal Necrolysis.  ¶see text for nature of clinical manifestations  624 
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Table 2:  The most significantly associated variants for immediate hypersensitivity reactions to β-lactams 625 
 626 
 Minor allele frequency Association analysis Association 
conditioned for HLA 
Haplotype¶ 
Association 
conditioned for 
rs71542416 
 Cases Controls Population 
reference cohort 
OR (95% 
CI) 
P OR (95% 
CI) 
P OR P 
HLA-DRB1*10:01 0.03 0.008 0.008 2.95 
(1.99-
4.36) 
6.0x10-8 - - 0.60 
90.19-
1.85) 
0.37 
HLA-DQA1*01:05 0.03 0.01 0.01 2.93 
(1.92-
4.46) 
5.4x10-7 - - 0.79 (0.32-
1.91) 
0.60 
rs71542416  0.03 0.006 0.008 5.17 
(3.40-
5.17) 
1.2x10-14 8.22 (2.68-
25.23) 
0.0002 - - 
rs114632839# 0.25 0.367 0.40 0.77 
(0.67-
0.89) 
0.0003 0.69 (0.60-
0.80) 
1.1x10-6 0.68 (0.59-
0.79) 
6.1x10-7 
 627 
Minor allele frequency for external data obtained from allelefrequncy.net for HLA alleles or GnomAD for SNPs; OR= Odd ratio of the logistic regression model correcting 628 
for population stratification; 95% CI=  95% confidence intervals of the Odd Ratio; P = logistic regression p-value; ¶HLA haplotype was HLA-DRB1*10:01- HLA-DQA1*01:05. 629 
#The marker rs114632839 has merged with rs3135392.  630 
 631 
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Table 3:  The association between HLA-DRB1*10:01 and rs71542416, and β-632 
lactam induced immediate hypersensitivity reactions across the different 633 
nationalities 634 
 635 
Ethnic 
cluster 
Cases (n*) Minor allele 
frequency 
Cases 
Minor allele 
frequency 
Controls 
OR (95% CI) P 
HLA-DRB1*10:01 
Italians  352 0.021 0.012 2.33 (1.15-4.73) 0.02 
Spanish  226 0.049 0.014 3.81 (2.27-6.42) 4.74x10-7 
Northern 
Europeans 
61 0.025 0.004 3.93 (1.17-13.21) 0.03 
rs71542416 
Italians  352 0.02 0.007 4.33 (1.98-9.49) 0.0002 
Spanish  226 0.05 0.008 6.80 (3.89-11.87) 1.69x10-11 
Northern 
Europeans 
61 0.02 0.004 4.42 (1.29-15.13) 0.02 
 636 
OR= Odd ratio of logistic regression model correcting for population stratification; 95%CI=  95% 637 
confidence intervals of the Odd Ratio; P = logistic regression p-value. *numbers represent 638 
homogeneous populations within clusters after PCA analysis. 639 
 640 
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Table 4:  Effect size of the association of HLA-DRB1*10:01 with immediate 644 
hypersensitivity reactions broken down by drug classes and individual drugs 645 
 646 
Drug Ethnicity* Cases 
(n) 
Case 
MAF 
OR 
(95% 
CI) 
P 
Cephalosporins Caucasian 162 0.019 2.03 
(0.82-
5.07) 
0.13 
   Cefaclor Caucasian 23 0 - - 
   Cefazolin Caucasian 17 0.059 6.12 
(1.32-
28.30) 
0.02 
   Cefotaxime Italian 17 0 - - 
   Ceftazidime Italian 17 0 - - 
   Ceftriaxone Italian 48 0.010 1.05 
(0.13-
8.33) 
0.96 
   Cefuroxime Caucasian 14 0.050 2.90 
(0.37-
22.76) 
0.31 
      
Penicillins Caucasian 501 0.036 3.07 
(2.04-
4.62) 
7.42x10-8 
   Amoxicillin Caucasian 166 0.042 3.48 
(1.92-
6,28) 
3.74x10-5 
   Ampicillin Italian 29 0.014 1.98 
(0.25-
15.79) 
0.52 
   Co-Amoxiclav Caucasian 218 0.034 2.85 
(1.60-
5.10) 
0.0004 
   Phenoxymethylpenicillin Caucasian 25 0.080 6.66 
(2.14-
20.79) 
0.001 
   Piperacillin Caucasian 18 0.028 2.32 
(0.29-
18.78) 
0.43 
   Bacampicillin Italian 21 0.024 2.09 
(0.26-
17.03) 
0.49 
 647 
*Ethnicity – Caucasian is applied to patients of Spanish, Italian and Northern European descent and 648 
confirmed by PCA analysis.  Where only one nationality was available for a particular drug, this is 649 
indicated and only appropriate matching controls were chosen. 650 
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OR= Odd ratio of logistic regression model correcting for population stratification; 651 
95% CI=  95% confident intervals of the Odd Ratio; P = logistic regression p-value; 652 
MAF; minor allele frequency 653 
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